These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 21388580)

  • 41. Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease.
    Baldwin CM; Keating GM
    CNS Drugs; 2007; 21(12):1039-55. PubMed ID: 18020483
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis.
    LeWitt PA; Poewe W; Elmer LW; Asgharnejad M; Boroojerdi B; Grieger F; Bauer L
    Clin Neuropharmacol; 2016; 39(2):88-93. PubMed ID: 26882318
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease.
    Giladi N; Boroojerdi B; Surmann E
    J Neural Transm (Vienna); 2013 Sep; 120(9):1321-9. PubMed ID: 23508526
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson's disease.
    Lau YH; Leta V; Rukavina K; Parry M; Ann Natividad J; Metta V; Chung-Faye G; Chaudhuri KR
    J Neural Transm (Vienna); 2022 Jul; 129(7):889-894. PubMed ID: 35503480
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial.
    Antonini A; Bauer L; Dohin E; Oertel WH; Rascol O; Reichmann H; Schmid M; Singh P; Tolosa E; Chaudhuri KR
    Eur J Neurol; 2015 Oct; 22(10):1400-7. PubMed ID: 26095948
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease.
    Güldenpfennig WM; Poole KH; Sommerville KW; Boroojerdi B
    Clin Neuropharmacol; 2005; 28(3):106-10. PubMed ID: 15965307
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The efficacy and safety of rotigotine transdermal patch for the treatment of sleep disorders in Parkinson's disease: a meta-analysis.
    Fei L; Zhou D; Ding ZT
    Sleep Med; 2019 Sep; 61():19-25. PubMed ID: 31272824
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome.
    Kenney C; Jankovic J
    Expert Opin Pharmacother; 2007 Jun; 8(9):1329-35. PubMed ID: 17563266
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The use of transdermal rotigotine in a patient with advanced Parkinson's disease and dysphagia.
    Christie J
    Palliat Med; 2007 Mar; 21(2):163-4. PubMed ID: 17443935
    [No Abstract]   [Full Text] [Related]  

  • 50. A controlled trial of rotigotine monotherapy in early Parkinson's disease.
    Parkinson Study Group
    Arch Neurol; 2003 Dec; 60(12):1721-8. PubMed ID: 14676046
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of motor and NMS of Parkinson's disease with the rotigotine transdermal system.
    Lyons KE
    Neurol Clin; 2013 Aug; 31(3 Suppl):vii-ix. PubMed ID: 23931955
    [No Abstract]   [Full Text] [Related]  

  • 52. Spotlight on rotigotine transdermal patch in Parkinson's disease.
    Sanford M; Scott LJ
    Drugs Aging; 2011 Dec; 28(12):1015-7. PubMed ID: 22117099
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rotigotine transdermal patch for the treatment of Parkinson's Disease.
    Perez-Lloret S; Rey MV; Ratti PL; Rascol O
    Fundam Clin Pharmacol; 2013 Feb; 27(1):81-95. PubMed ID: 22320451
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.
    Giladi N; Nicholas AP; Asgharnejad M; Dohin E; Woltering F; Bauer L; Poewe W
    J Parkinsons Dis; 2016 Oct; 6(4):741-749. PubMed ID: 27567886
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcomes of rotigotine clinical trials: effects on motor and nonmotor symptoms of Parkinson's disease.
    Lyons KE; Pahwa R
    Neurol Clin; 2013 Aug; 31(3 Suppl):S51-9. PubMed ID: 23931954
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of Rotigotine on REM Sleep Behavior Disorder in Parkinson Disease.
    Wang Y; Yang Y; Wu H; Lan D; Chen Y; Zhao Z
    J Clin Sleep Med; 2016 Oct; 12(10):1403-1409. PubMed ID: 27568909
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transdermal rotigotine patch in Parkinson's disease with a history of intestinal operation.
    Ogawa T; Oyama G; Hattori N
    BMJ Case Rep; 2018 Jun; 2018():. PubMed ID: 29909386
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transdermal rotigotine in early stage Parkinson's disease: a randomized, double-blind, placebo-controlled trial.
    Mizuno Y; Nomoto M; Kondo T; Hasegawa K; Murata M; Takeuchi M; Ikeda J; Tomida T; Hattori N;
    Mov Disord; 2013 Sep; 28(10):1447-50. PubMed ID: 23801585
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain.
    Rascol O; Zesiewicz T; Chaudhuri KR; Asgharnejad M; Surmann E; Dohin E; Nilius S; Bauer L
    J Clin Pharmacol; 2016 Jul; 56(7):852-61. PubMed ID: 26626320
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rotigotine transdermal delivery for the treatment of Parkinson's disease.
    Rascol O; Perez-Lloret S
    Expert Opin Pharmacother; 2009 Mar; 10(4):677-91. PubMed ID: 19239399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.